



# Resource impact template

Resource impact

Published: 28 November 2025

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for migraine:

- [Atogepant for preventing migraine](#) (2024) NICE technology appraisal guidance 973
- [Rimegepant for treating migraine](#) (2023) NICE technology appraisal guidance 919
- [Rimegepant for preventing migraine](#) (2023) NICE technology appraisal guidance 906
- [Eptinezumab for preventing migraine](#) (2023) NICE technology appraisal guidance 871
- [Fremanezumab for preventing migraine](#) (2022) NICE technology appraisal guidance 764
- [Erenumab for preventing migraine](#) (2021) NICE technology appraisal guidance 682
- [Galcanezumab for preventing migraine](#) (2020) NICE technology appraisal guidance 659
- [Botulinum toxin type A for the prevention of headaches in adults with chronic migraine](#) (2012) NICE technology appraisal guidance 260